EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin Modulates Apoptosis and Autophagy Pathways in Lung Cancer Through Network Pharmacology and In Vitro Analysis

Ola A El-Feky iD, Sara M Hamouda iD, Manar Mohammed El Tabaa iD, Sally E Abu-Risha, Ahmed B M Mehany, Othman F Abdelzaher, Samar A El-Adawy iD

Journal of Biochemical and Molecular Toxicology · 2026-11 · 40 (11)

DOI: 10.1002/jbt.71174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 07.11.2026. Verfasst von Ola A El-Feky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. Hauptthemen laut MEDLINE: Apoptosis, Autophagy, Lung Neoplasms, Glucosides. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains a major cause of cancer‐related mortality, highlighting the need for novel therapeutic strategies. Empagliflozin (EMPA), a sodium–glucose cotransporter 2 inhibitor, has demonstrated emerging anticancer activity; however, its effects on apoptosis–autophagy crosstalk in lung cancer remain incompletely understood. This study investigated the anticancer effects of EMPA and the influence of hydroxychloroquine (HCQ)‐mediated autophagy inhibition in A549 and HOP‐92 human lung cancer cells. Network pharmacology with explicit database association‐score cutoffs, and molecular docking validated by redocking of a co‐crystallized reference ligand, were used to identify potential EMPA‐associated targets and pathways. Cytotoxicity of EMPA, HCQ, and their combination was evaluated by MTT assay, followed by combination index and Bliss analyses. Cell‐cycle distribution and apoptosis were assessed by flow cytometry. Expression of apoptosis‐ and autophagy‐related markers was evaluated by RT‐qPCR, cleaved caspase‐3 analysis, and Western blotting. Network analysis identified 239 overlapping EMPA–lung cancer targets, of which 46 were retained after applying an Open Targets association‐score cutoff of 0.30. Docking, validated by reproducing the erlotinib crystal pose in the EGFR kinase domain (heavy‐atom RMSD 1.30 ± 0.02 Å), indicated that EMPA can be accommodated at surface sites of ANXA8 (−7.6 kcal/mol) and the p62/SQSTM1 ZZ domain (−7.0 kcal/mol) and within the ligand‐binding pocket of PPARγ (−7.5 kcal/mol; PDB 8BF1, the PPARγ–PGC‐1α coactivator complex). EMPA reduced cell viability in both cell lines, with greater sensitivity in A549 cells. Combining EMPA with HCQ markedly reduced IC 50 values and demonstrated synergistic interactions at IC 50 . EMPA altered cell‐cycle progression and increased apoptotic cell death, accompanied by enhanced BAX and CASP3 expression and cleaved caspase‐3 activation. EMPA increased LC3‐II without p62 accumulation, consistent with increased autophagic activity, whereas HCQ‐containing treatments induced LC3‐II and p62 accumulation and enhanced apoptotic signaling. EMPA exerts antiproliferative and pro‐apoptotic effects in lung cancer cells while modulating autophagy. Inhibition of lysosomal autophagic degradation by HCQ enhances EMPA‐mediated cytotoxicity and apoptosis, supporting further investigation of this combination as an anticancer strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisAutophagyLung NeoplasmsGlucosidesBenzhydryl CompoundsHumansMolecular Docking SimulationNetwork PharmacologyA549 CellsHydroxychloroquineSignal TransductionCell Line, Tumor

Stichwörter der Autor:innen

LC3‐IISGLT2 inhibitorapoptosisautophagyempagliflozinhydroxychloroquinelung cancerp62

Substanzen

GlucosidesBenzhydryl CompoundsempagliflozinHydroxychloroquine

Autor:innen und Institutionen

  • Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Alsalam University, Kafr El, Egypt.
  • Pharmacology & Environmental Toxicology, Environmental Studies & Research Institute (ESRI), University of Sadat City, Sadat City, Egypt.
  • Pharmacology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Ola A El-Feky, Sara M Hamouda, Manar Mohammed El Tabaa, Samar A El-Adawy

Zitieren

APA

El-Feky, O. A., Hamouda, S. M., Tabaa, M. M. E., Abu-Risha, S. E., Mehany, A. B. M., Abdelzaher, O. F., & El-Adawy, S. A. (2026). Empagliflozin Modulates Apoptosis and Autophagy Pathways in Lung Cancer Through Network Pharmacology and In Vitro Analysis. Journal of Biochemical and Molecular Toxicology, 40(11). https://doi.org/10.1002/jbt.71174

Vancouver

El-Feky OA, Hamouda SM, Tabaa MME, Abu-Risha SE, Mehany ABM, Abdelzaher OF, et al. Empagliflozin Modulates Apoptosis and Autophagy Pathways in Lung Cancer Through Network Pharmacology and In Vitro Analysis. Journal of Biochemical and Molecular Toxicology. 2026;40(11). doi:10.1002/jbt.71174

BibTeX
@article{ElFeky2026,
  author = {El-Feky, Ola A and Hamouda, Sara M and Tabaa, Manar Mohammed El and Abu-Risha, Sally E and Mehany, Ahmed B M and Abdelzaher, Othman F and El-Adawy, Samar A},
  title = {Empagliflozin Modulates Apoptosis and Autophagy Pathways in Lung Cancer Through Network Pharmacology and In Vitro Analysis},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  volume = {40},
  number = {11},
  doi = {10.1002/jbt.71174}
}
Kostenlos starten →